$ETSY

Silverman Josh sold $3.4M of ETSY

Silverman Josh sold 41,108 shares of ETSY INC (ETSY) at an average of $83.11 ($82.51–$83.28, $3.42M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Silverman Josh
Published Aug 4, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ETSY
Neutral
high confidence
Mentioned
$ETSY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ETSYNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale size and timing (41,108 shares on 2026-08-03) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure makes it less actionable as a standalone catalyst.

03

What to watch

The filing does not indicate intent beyond the plan, and it provides no performance or guidance context, so the signal quality is limited.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-04 for sales executed 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Etsy, reported via EDGAR.

Company-level read

Ticker impact

$ETSYNeutralHigh confidence
Context

Etsy director Josh Silverman sold 41,108 shares in open-market transactions totaling about $3.42M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any reaction is likely muted and short-lived.

Evidence & confidence

Form 4 shows an open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single 10b5-1 director sale.

None indicated.

None indicated.

Counterpoint

Insider sales can still coincide with private views on valuation or liquidity needs, even when 10b5-1 is used; traders may watch for follow-on sales or changes in buying behavior.

Key entities

  • ETSY

    Etsy Inc., the company whose director transaction is disclosed.

  • Josh Silverman

    Director who sold 41,108 shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WMTMed

Retailers Report AI-Driven Sales, Bigger Baskets in Q2 Earnings

Walmart, Amazon, and Target reported Q2 earnings showing AI-driven sales growth. Walmart's eCommerce grew 23%, with AI assistant users spending 40% more. Amazon's Alexa for Shopping saw active users nearly double. Target's digital traffic from AI platforms grew over 3.5x faster than the industry average. Albertsons saw a 10-26% increase in order value with AI tools. Shopify's AI-referred traffic and orders tripled, but AI's impact on discovery-driven retail remains uncertain.

$ETSYHigh

Bank of America Resets Etsy Stock Price Target After Event

Bank of America upgraded Etsy to Buy, raising its price target to $105 from $88, citing structural growth. The bank expects mid-single-digit gross merchandise sales growth, higher profitability, and increased shareholder returns. Etsy's new management team is seen as key to reinvigorating growth. BofA raised its fiscal 2027 estimates for gross merchandise sales, EBITDA, and EPS.

$DEMed

Premarket movers: Deere jumps following upbeat Q3, Wolfspeed plunges

Deere shares rose 5.1% after reporting stronger-than-expected Q3 results, with EPS of $5.10 and net sales of $11B. CrowdStrike fell 2.8% following its CTO's departure. Advance Auto Parts dropped 15.9% due to lower normalized earnings. Etsy gained 3.9% after a BofA upgrade. Ultragenyx surged 11.1% on FDA approval for a gene therapy. Moderna fell 13% after a prior surge. Wolfspeed plunged 10.5% on wider-than-expected Q4 loss. Webull rose 13.8% on strong Q2 results.